Regarding: ‘Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib’

Detalles Bibliográficos
Autor principal: Porta, C
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2853087/
https://www.ncbi.nlm.nih.gov/pubmed/20179707
http://dx.doi.org/10.1038/sj.bjc.6605585
Descripción
Sumario:

Ejemplares similares